Alterity Therapeutics Limited

NasdaqCM:ATHE Stok Raporu

Piyasa değeri: US$10.5m

Alterity Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Alterity Therapeutics has a total shareholder equity of A$13.8M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$19.2M and A$5.4M respectively.

Anahtar bilgiler

0%

Borç/özkaynak oranı

AU$0

Borç

Faiz karşılama oranın/a
NakitAU$12.64m
EşitlikAU$13.80m
Toplam yükümlülüklerAU$5.43m
Toplam varlıklarAU$19.22m

Son finansal sağlık güncellemeleri

Recent updates

Alterity launches phase 2 study of ATH434 for multiple system atrophy in UK

Aug 25

Alterity begins dosing in mid-stage study of ATH434 for multiple system atrophy

Jul 06

Alterity: The Alternate Prana With New U.S. Patents In Iron Chaperone Technology

Sep 16

Alterity Therapeutics names Dr. David Stamler as CEO

Jan 07

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

Dec 21

Alterity Therapeutics nabs US patent for compounds for neurodegenerative disorders

Nov 16

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ATHE's short term assets (A$19.0M) exceed its short term liabilities (A$5.4M).

Uzun Vadeli Yükümlülükler: ATHE's short term assets (A$19.0M) exceed its long term liabilities (A$51.9K).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ATHE is debt free.

Borcun Azaltılması: ATHE had no debt 5 years ago.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ATHE has sufficient cash runway for more than a year based on its current free cash flow.

Tahmini Nakit Akışı: Insufficient data to determine if ATHE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Sağlıklı şirketleri keşfedin